KALA BIO, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KALA BIO, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $45.0K | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.98M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($38.51M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($42.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($44.82M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($142.61M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($104.33M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($94.35M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($66.74M) | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | ($42.21M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($33.17M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.16M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($40.98M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($39.66M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($81.71M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($130.25M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($96.23M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($88.22M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($64.72M) | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | ($39.88M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($32.67M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $18.35M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $27.28M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $29.29M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $29.01M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $25.03M | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $11.38M | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $20.57M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $65.04M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $105.06M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $81.07M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $65.02M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $35.43M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $10.87M | Mar 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.99M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($29.38M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($27.93M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($78.91M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($108.24M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($90.69M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($92.72M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($54.12M) | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | ($34.10M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($27.35M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.34M | Feb 12, 2020 |
| FY2019 | Dec 31, 2018 | $1.58M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $480.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $153.0K | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $252.0K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.49M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $55.48M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $55.95M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $86.82M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $139.43M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $221.61M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $154.32M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $220.97M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $116.55M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $46.33M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $43.15M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $48.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $67.85M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $122.62M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $121.61M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $124.63M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $115.99M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $26.87M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $15.70M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.00M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $12.33M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $7.50M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $18.97M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $16.80M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $100.00M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $29.69M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $104.98M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $89.68M | Feb 12, 2020 |
| FY2018 | Dec 31, 2016 | ($87.76M) | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($694.90M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($667.92M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($629.41M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($587.21M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($542.39M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($399.78M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($295.46M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($201.11M) | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | ($134.37M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($92.14M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.56M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $51.18M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $50.90M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $70.50M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $92.14M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $77.26M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $85.45M | Feb 25, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $29.28M | Apr 15, 2026 |
| FY2022 | Dec 31, 2022 | $43.30M | Mar 3, 2023 |
| FY2022 | Dec 31, 2021 | $80.00M | Mar 3, 2023 |
| FY2020 | Dec 31, 2020 | $75.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $75.00M | Feb 12, 2020 |
| FY2018 | Dec 31, 2018 | $75.00M | Mar 12, 2019 |
| FY2017 | Dec 31, 2017 | $18.89M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (17) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (29) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (108) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (17) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (29) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (108) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 29, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.85M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 6.09M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 2.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.71M | Mar 29, 2024 |
| FY2023 | Oct 20, 2022 | 1 | Mar 29, 2024 |
| FY2023 | Oct 19, 2022 | 50 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 1.32M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 58.92M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 36.09M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 33.86M | Feb 12, 2020 |